HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Resveratrol as a new inhibitor of immunoproteasome prevents PTEN degradation and attenuates cardiac hypertrophy after pressure overload.

Abstract
Sustained cardiac hypertrophy is a major cause of heart failure (HF) and death. Recent studies have demonstrated that resveratrol (RES) exerts a protective role in hypertrophic diseases. However, the molecular mechanisms involved are not fully elucidated. In this study, cardiac hypertrophic remodeling in mice were established by pressure overload induced by transverse aortic constriction (TAC). Cardiac function was evaluated by echocardiography and invasive pressure-volume analysis. Cardiomyocyte size was detected by wheat germ agglutinin staining. The protein and gene expressions of signaling mediators and hypertrophic markers were examined. Our results showed that administration of RES significantly suppressed pressure overload-induced cardiac hypertrophy, fibrosis and apoptosis and improved in vivo heart function in mice. RES also reversed pre-established hypertrophy and restoring contractile dysfunction induced by chronic pressure overload. Moreover, RES treatment blocked TAC-induced increase of immunoproteasome activity and catalytic subunit expression (β1i, β2i and β5i), which inhibited PTEN degradation thereby leading to inactivation of AKT/mTOR and activation of AMPK signals. Further, blocking PTEN by the specific inhibitor VO-Ohpic significantly attenuated RES inhibitory effect on cardiomyocyte hypertrophy in vivo and in vitro. Taken together, our data suggest that RES is a novel inhibitor of immunoproteasome activity, and may represent a promising therapeutic agent for the treatment of hypertrophic diseases.
AuthorsChen Chen, Lei-Xin Zou, Qiu-Yue Lin, Xiao Yan, Hai-Lian Bi, Xin Xie, Shuai Wang, Qing-Shan Wang, Yun-Long Zhang, Hui-Hua Li
JournalRedox biology (Redox Biol) Vol. 20 Pg. 390-401 (01 2019) ISSN: 2213-2317 [Electronic] Netherlands
PMID30412827 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.
Chemical References
  • Biomarkers
  • Cardiotonic Agents
  • Proteasome Inhibitors
  • Proto-Oncogene Proteins c-akt
  • TOR Serine-Threonine Kinases
  • PTEN Phosphohydrolase
  • PTEN protein, human
  • Proteasome Endopeptidase Complex
  • Resveratrol
Topics
  • Animals
  • Biomarkers
  • Blood Pressure
  • Cardiomegaly (diagnosis, drug therapy, metabolism, physiopathology)
  • Cardiotonic Agents (pharmacology)
  • Cells, Cultured
  • Disease Models, Animal
  • Echocardiography
  • Heart Function Tests
  • Male
  • Mice
  • Models, Molecular
  • Myocytes, Cardiac (drug effects, metabolism)
  • PTEN Phosphohydrolase (metabolism)
  • Proteasome Endopeptidase Complex (immunology, metabolism)
  • Proteasome Inhibitors (pharmacology)
  • Proteolysis (drug effects)
  • Proto-Oncogene Proteins c-akt (metabolism)
  • Rats
  • Resveratrol (pharmacology)
  • TOR Serine-Threonine Kinases

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: